Carlos Becerra
About
Carlos Becerra is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Carlos Becerra has authored 98 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 32 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carlos Becerra's work include Colorectal Cancer Treatments and Studies (20 papers), Pancreatic and Hepatic Oncology Research (16 papers) and Cancer Treatment and Pharmacology (14 papers). Carlos Becerra is often cited by papers focused on Colorectal Cancer Treatments and Studies (20 papers), Pancreatic and Hepatic Oncology Research (16 papers) and Cancer Treatment and Pharmacology (14 papers). Carlos Becerra collaborates with scholars based in United States, Spain and Canada. Carlos Becerra's co-authors include Udit Verma, Richard B. Gaynor, Eugene P. Frenkel, Rama Mohan Surabhi, Razelle Kurzrock, Donna S. Cox, Keith T. Flaherty, Michael S. Gordon, Jeffrey R. Infante and Howard A. Burris and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
Carlos Becerra
92 papers receiving 2.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carlos Becerra United States | 24 | 1.4k | 1.1k | 400 | 398 | 379 | 98 | 2.5k | ||
| Robert D. Ladner United States | 32 | 1.9k 1.4× | 1.6k 1.5× | 318 0.8× | 375 0.9× | 376 1.0× | 51 | 3.3k | ||
| Scott A. Boerner United States | 23 | 1.2k 0.9× | 852 0.8× | 238 0.6× | 337 0.8× | 334 0.9× | 40 | 2.2k | ||
| Prafulla C. Gokhale United States | 24 | 1.4k 1.0× | 779 0.7× | 358 0.9× | 318 0.8× | 319 0.8× | 84 | 2.4k | ||
| Melissa J. LaBonte United States | 27 | 1.2k 0.9× | 1.3k 1.2× | 368 0.9× | 393 1.0× | 526 1.4× | 78 | 2.6k | ||
| Volker Wacheck Austria | 35 | 2.3k 1.7× | 1.0k 0.9× | 496 1.2× | 480 1.2× | 474 1.3× | 113 | 3.6k | ||
| David A. Proia United States | 30 | 1.9k 1.3× | 945 0.9× | 323 0.8× | 376 0.9× | 362 1.0× | 57 | 2.6k | ||
| Argun Akçakanat United States | 26 | 1.4k 1.0× | 1.4k 1.4× | 600 1.5× | 525 1.3× | 568 1.5× | 52 | 2.9k | ||
| Helmout Modjtahedi United Kingdom | 30 | 1.1k 0.8× | 1.4k 1.3× | 268 0.7× | 548 1.4× | 333 0.9× | 81 | 2.5k | ||
| Donna Headlee United States | 24 | 1.5k 1.1× | 1.1k 1.0× | 330 0.8× | 559 1.4× | 328 0.9× | 34 | 2.7k | ||
| Guocan Wang United States | 20 | 1.6k 1.2× | 862 0.8× | 466 1.2× | 542 1.4× | 641 1.7× | 33 | 2.6k |
Countries citing papers authored by Carlos Becerra
Since
Specialization
Citations
This map shows the geographic impact of Carlos Becerra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Becerra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Becerra more than expected).
Fields of papers citing papers by Carlos Becerra
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Carlos Becerra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Becerra. The network helps show where Carlos Becerra may publish in the future.
Co-authorship network of co-authors of Carlos Becerra
This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Becerra. A scholar is included among the top collaborators of Carlos Becerra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Becerra. Carlos Becerra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Davar, Diwakar, Zeynep Eroglu, Mohammed Milhem, et al.. (2025). Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B. Clinical Cancer Research. 31(16). 3443–3451.
2.
Chung, Vincent, Angela Alistar, Carlos Becerra, et al.. (2025). Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. The Oncologist. 30(1).
3.
Punekar, Salman R., Meredith Pelster, Carlos Becerra, et al.. (2024). An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation.. Journal of Clinical Oncology. 42(16_suppl). TPS2677–TPS2677.
4.
Stein, Mark N., Ecaterina E. Dumbrava, Benjamin A. Teply, et al.. (2024). PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nature Communications. 15(1). 10743–10743.
5.
Davar, Diwakar, Zeynep Eroglu, Mohammed Milhem, et al.. (2023). 596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy. SHILAP Revista de lepidopterología. A678–A678.
6.
Saif, Muhammad Wasif, Carlos Becerra, Marwan Fakih, et al.. (2021). A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemotherapy and Pharmacology. 88(3). 485–497.
7.
Saif, Muhammad Wasif, Lee S. Rosen, Michelle A. Rudek, et al.. (2019). Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. British Journal of Clinical Pharmacology. 85(6). 1239–1246.
8.
Abramson, Vandana G., Mafalda Oliveira, Andrés Cervantes, et al.. (2019). A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Research and Treatment. 178(1). 121–133.
9.
Kandimalla, Raju, Feng Gao, Takatoshi Matsuyama, et al.. (2018). Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer. Clinical Cancer Research. 24(16). 3867–3877.
10.
Becerra, Carlos, et al.. (2018). Locally advanced carcinosarcoma of the pancreas. Baylor University Medical Center Proceedings. 31(2). 210–212.
11.
Hidalgo, Manuel, Ron Epelbaum, Ravit Geva, et al.. (2018). Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. Journal of Clinical Oncology. 36(5_suppl). 88–88.
12.
Yoshida, Kazuhiro, Shusuke Toden, Wenhao Weng, et al.. (2016). Su2060 Curcumin Inhibits Polycomb Repressive Complex 2 through lncRNA-PVT1 and Enhances Gemcitabine Sensitivity in Chemoresistant Pancreatic Cancer. Gastroenterology. 150(4). S624–S624.
13.
Becerra, Carlos, Ramón Salazar, Rocio García‐Carbonero, et al.. (2011). Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 29(15_suppl). 3525–3525.
14.
Nagaraj, Srinivas, Je-In Youn, Hannah Weber, et al.. (2010). Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer. Clinical Cancer Research. 16(6). 1812–1823.
15.
Hanna, Nasser H., et al.. (2009). Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. Journal of Clinical Oncology. 27(15_suppl). 4557–4557.
16.
Becerra, Carlos, et al.. (2008). Phase I Dose Escalation Study With Irinotecan, Capecitabine, Epirubicin, and Granulocyte Colony-Stimulating Factor Support for Patients With Solid Malignancies. American Journal of Clinical Oncology. 31(3). 219–225.
17.
Guo, Jun, Anwu Zhou, Yu‐Cai Fu, et al.. (2006). Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacologica Sinica. 27(10). 1375–1381.
18.
Becerra, Carlos, Eugene P. Frenkel, Raheela Ashfaq, & Richard B. Gaynor. (2003). Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. International Journal of Cancer. 105(6). 868–872.
19.
Bajetta, E., Luigi Celio, Roberto Buzzoni, et al.. (2003). Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer. Annals of Oncology. 14(10). 1543–1548.
20.
Connell, F., et al.. (1998). Palmitoyl-Protein thioesterase deficiency in a novel granular variant of LINCL. Pediatric Neurology. 18(2). 119–123.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert D. Ladner Breakdown of academic impact, for papers by Scott A. Boerner Breakdown of academic impact, for papers by Prafulla C. Gokhale Breakdown of academic impact, for papers by Melissa J. LaBonte Breakdown of academic impact, for papers by Volker Wacheck Breakdown of academic impact, for papers by David A. Proia Breakdown of academic impact, for papers by Argun Akçakanat Breakdown of academic impact, for papers by Helmout Modjtahedi Breakdown of academic impact, for papers by Donna Headlee Breakdown of academic impact, for papers by Guocan Wang